Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breast Cancer
Intervention: Anastrozole (Drug)
Sponsored by: AstraZeneca
Official(s) and/or principal investigator(s):
H Brasch, Study Director, Affiliation: AstraZeneca Germany
The purpose of this study is the initial/followed by 5 year adjuvant therapy with
Official title: Postmenopausal Women With Early Hormone-Receptor Positive Breast Cancer/no Metastasis
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Primary outcome: evaluation of Anastrozole therapy as adjuvant treatment in post.menopausal women with not advanced breast cancer únder naturalistic conditions
description of population treated with anastrozole
further information about the change of specific laboratory parameters
Minimum age: N/A.
Maximum age: N/A.
- Postmenopausal women with early hormone receptor positive breast cancer/no metastasis
Locations and Contacts
Starting date: May 2005
Last updated: March 19, 2008